A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
Clinical trial NCT05743634 · COMPLETED
Trial details
- NCT number
- NCT05743634
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-22
- Primary completion
- 2023-02-13
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.